Obermatt

Labcorp

NYQ:LH · US5049221055
Health Care Providers & ServicesX-Large

360

40
EV / EBIT60
Price / Owner Earnings38
Owner Earnings Yield74
Dividend Yield97
Price/Sales93
EV / Gross Profit37
Price/Book59
Return on Capital70
Cash Return on Capital67
Return on Equity70
EBIT Margin79
Gross Profitability33
Cash Conversion46
Accruals24
Owner Earnings Margin80
Sales growth69
Profit Growth100
Long-Term EPS Growth34
Owner Earnings Growth64
Reinvestment36
Price momentum32
Debt load26
Refinancing97
Debt Payback46
Liquidity100
Analyst ratings16
Opinion Changes54
Price Target Upside43
Market mood94
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Labcorp clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryHealth Care Providers & Services
SizeX-Large
TypePublic Company
ExchangeNYSE
Founded2024
Employees26,771
ISINUS5049221055
Last UpdateApr 2, 2026
Themes
Infectious DiseasesEndocrinologyCardiovascularGeneticsPharmacovigilanceWomen's HealthHealth DiagnosticsOncologyBiotechnologyEducationHealth CareInnovation ManagementMedical

Description

Labcorp Holdings Inc. provides laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The company provides insights and accelerates innov…

Analysis

Middle-of-the-road

Labcorp Holdings Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is fair. You pay 18.0× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 5% yearly growth; analysts expect 9%. The price, in other words, assumes less than the experts do.

The trajectory is moderate and the balance sheet is adequate. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
100
2023202420252026

All-time high

100

Jun 2026

All-time low

39

Aug 2023

Average rank

76

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
93
35
28
35
Price/Earnings
11
59
45
57
Price/Book
59
39
49
64
Dividend Yield
97
80
81
86
Value (overall)
87
60
69
74

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Labcorp with its peers
Quest Diagnostics
NYQ:DGX
35
CountryUSA
IndustryHealth Care Providers & Services
SizeX-Large
Full Stock Analysis →
Mistras
NYQ:MG
33
CountryUSA
IndustryProfessional Services
SizeMedium
Full Stock Analysis →
Schrödinger
NSQ:SDGR
14
CountryUSA
IndustryHealth Care Technology
SizeMedium
Full Stock Analysis →
Adaptive Biotechnologies
NSQ:ADPT
20
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Spero Therapeutics
NSQ:SPRO
77
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Rocket Pharmaceuticals
NMQ:RCKT
31
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →